Feed GOVX
GO
GeoVax Labs, Inc. GOVX · NASDAQ
$0.24 -7.56% (-$0.02)
Summary
55 / 100 · Bulios Score
Valuation 100Growth 78Profitability -Quality 0Debt 92Stability 1
What speaks for it
- Revenue grew by 213% a year over the last 3 years.
- It holds more cash than debt: $3.14M against $323.1K.
What to watch
- It passes only 2 of the 9 points of the Piotroski financial health test.
- The price moves much more than the market (beta 3.69).
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapIs it growing?
Yes, fastRevenue (USD)
2021202220232024202520262027
Diluted EPS (USD)
2021202220232024202520262027
- Analyst estimate
Revenue grew by 6.4% a year over 5 years. Over the last 3 years it grew by 213% a year.
Growth in detailDoes it make money?
Over the last 12 months it made a loss of $20.4M.
Profitability in detailIs it financially healthy?
YesCash and short-term investments $3.14M
Debt $323.1K
Free cash flow over 12 months -$18.4M
Over the last 12 months it spent more cash than it brought in. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 6
- Hold 1
- Sell 0
Today's price within the analysts' price targets
Today's price $0.24 Average target $100
$0.24 $100
The average target of $100 is 41,864% above today's price. 86% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2022By product
- NIH Grants 100%
By region
The company reports no revenue by region.
NIH Grants brings in 100% of revenue.
Segments in detail